NanoViricides Inc. (NNVC)

[DaysOnTheBeach]

PR: USAMRIID to Study NNVC antivirals as Ebola Treatment

http://biz.yahoo.com/bw/071029/20071029005971.html?.v=1

USAMRIID to Study NanoViricides Against Ebola

Monday October 29, 10:41 am ET

Material Transfer Agreement Signed

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that they have executed a Material Transfer Agreement (MTA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). This joint R&D effort will enable USAMRIID scientists to test the efficacy of several NanoViricides, Inc. anti-viral nanomedicines against deadly hemorrhagic fever viruses at the Ft. Detrick, Maryland BSL4 facilities

Ebola virus, a highly pathogenic and usually fatal virus found in Africa, will be the initial focus of this joint effort. Animal studies as well as in vitro testing are planned.

“This collaboration is designed to test the efficacy of the nanoviricide approach against this pathogen,” said NanoViricides, Inc. President Dr. Anil Diwan. It is hoped that success against the deadly Ebola virus will lead to further success against other virulent pathogens such as hanta viruses, Marburg virus, Junin virus, Machupo virus, and Rift Valley fever virus. There are currently no FDA-approved treatment options for these diseases.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute’s mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The Institute is working to develop therapeutics for a number of agents, such as Ebola virus, plague, several toxins, and orthopoxviruses.